Kelowna, British Columbia-based Lexaria Bioscience Corp. (OTC: LXRP) (CSE: LXX), a drug delivery technology innovator, announced the launch of ChrgD+, a water-soluble, ready-mix hemp supplement powder designed to be added to any drink.
ChrgD+ incorporates multi-spectrum hemp oil, processed using Lexaria DehydraTECH technology, allowing more effective delivery of hemp oil to the body from any existing beverage, hot or cold. Lexaria develops and out-licenses DehydraTECH delivery technology. It promotes healthier ingestion, lower overall dosing and higher effectiveness of lipophilic active molecules.
Weighing 2 grams per pouch, ChrgD+ packets can be carried in a shirt pocket or purse, and consumed anywhere in a soft drink, coffee or energy drink. It is nearly flavorless and odorless, offering minimal impact to a beverage other than a sparkle effect to remind consumers they are getting ChrgD+.
“It’s a simple way to add a multi-spectrum powdered hemp supplement to your favorite beverage at any time and enjoy its fast-acting, non-altered taste with no oily residue”, said Chris Bunka, CEO of Lexaria Bioscience. “Lexaria’s ChrgD+ product format is being evaluated by others for use in their psychoactive cannabinoids products sector as per our proven track record as a technology provider to the industry.”
Lexaria engaged Cultivating Wellness Inc, a California-based brand development and distribution company, to create the ChrgD+ premium brand.
{{cta(’69f63bd3-e695-415f-8c83-b207c29317a6′)}}
Cultivating Wellness’ distribution network reaches tens of thousands of retail buyers in c-stores, grocery chains, specialty retail, and national accounts. “Now that ChrgD+ has been launched, we’re turning our attention to distributing the product through our growing nationwide distribution network,’ said Lisa Hannah, President of Cultivating Wellness.
Lexaria’s lab has other product concepts that will use DehydraTECH technology. Lexaria has received multiple patents for the delivery of both psychoactive and non-psychoactive cannabinoids; nicotine; vitamins, and certain pain relievers.
Lexaria has eight patents granted in the USA and in Australia and has filed over 50 patent applications 
worldwide across ten patent families. It’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
Want to learn about other great cannabis investment opportunities? Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We’ll keep you informed on all things cannabis and even help you determine which cannabis companies have the highest growth potential.
About Lexaria
Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has eight patents granted in the USA and in Australia and has filed over 50 patent applications worldwide across ten patent families. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.
For information about distributing ChrgD+, email: orders@cultivatingwellness.co
Source Lexaria press release